NCT02810509 is a clinical trial in Atrial Fibrillation, sponsored by Inje University.

Who is sponsoring NCT02810509?

NCT02810509 is sponsored by Inje University.

What condition does NCT02810509 study?

NCT02810509 studies Atrial Fibrillation, Stroke.

Is NCT02810509 still recruiting?

NCT02810509 is currently completed. Last updated 8 August 2019.

Are results published for NCT02810509?

Yes — primary outcome results have been posted to ClinicalTrials.gov. See the outcomes section above for details.

Last reviewed 2019-08-08 · How we verify

NCT02810509

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Quality of Anticoagulation With Warfarin in Patient With Atrial Fibrillation for Secondary Stroke Prevention in Korea

Completed Results posted Last updated 8 August 2019

What this trial tests

trial in Atrial Fibrillation in 1,814 participants. Completed in 1 October 2016.

Timeline

1 June 2015

Primary endpoint
1 October 2016

1 October 2016

Quick facts

Lead sponsor	Inje University
Status	Completed
Study type	OBSERVATIONAL
Enrollment	1,814
Start date	1 June 2015
Primary completion	1 October 2016
Estimated completion	1 October 2016
Sites	18 locations across South Korea

Conditions studied

Atrial Fibrillation — all drugs for Atrial Fibrillation →
Stroke — all drugs for Stroke →

Sponsor

Inje University

Who can join

Eligibility, any sex, with Atrial Fibrillation or Stroke. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Time in TTR, the Percentage of Time in the Therapeutic Range of INR Between 2.0-3.0.
Time frame: We will analyze INR data of patients who had AF-related ischemic stroke and were treated with warfarin therapy at least for more than 7 days of warfarin adjustment period. (The INR follow up duration: 1 ~ maximum 3 years)
The primary outcome is TTR as measured by the percentage of time in the therapeutic range of INR between 2.0-3.0, using the Rosendaal linear interpolation method.

Sponsor's own description

The current study aims to assess the quality of anticoagulation with warfarin in real world practice of secondary stroke prevention in Korean patients with Atrial fibrillation (AF) and to explore predictors for poor International Normalized Range (INR) control.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Atrial Fibrillation

Currently open trials in the same condition.

NCT07429214 — A Study of VARIPULSE Catheter and TRUPULSE Generator With VARIPULSE Pro Software in Participants With PAF or PsAF · NA · recruiting
NCT07271238 — Feasibility Study on the VERAFEYE Imaging and Navigation System for Guided Catheter Ablation Procedures · NA · recruiting
NCT07388108 — Atrial Dyssynchrony to Predict Arrhythmias in the Postoperative Setting of Cardiovascular Surgery. · recruiting
NCT07428967 — AV Node Ablation and CONDUCTion System Pacing for Atrial Fibrillation With Preserved Left Ventricular Function · NA · recruiting
NCT06650995 — AlEX-DHF: Ablation and Exercise in Diastolic Heart Failure · NA · recruiting

Other Inje University trials

Trials by the same sponsor.

NCT07318428 — AI-Assisted Detection of Posterior Segment Diseases: DR, AMD, RVO, and Glaucoma · NA · enrolling by invitation
NCT05636189 — Effect of Prewarming During Induction of General Anesthesia Combined With Warmed Intravenous Fluid on Core Temperature. · NA · completed
NCT05766644 — App-based Education Program for CKD · NA · unknown
NCT05514405 — Effect of Remimazolam and Propofol on Postoperative Delirium · NA · recruiting
NCT05439057 — Effect of Remimazolam on Postoperative Nausea and Vomiting · NA · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02810509 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Inje University
Last refreshed: 8 August 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02810509.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing